Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hanbyeol Kwon"'
Publikováno v:
2021 18th International SoC Design Conference (ISOCC).
Autor:
Eunyoung Lee, Kyu Yeon Jun, Jung Min Nam, Youngjoo Kwon, Younghwa Na, Yeung Bae Jin, Hanbyeol Kwon, Yun Sil Lee, Kyung Hwa Jeon
Publikováno v:
European Journal of Pharmaceutical Sciences. 50:181-190
Dithiiranylmethyloxy azaxanthone (CHO10), which was discovered by screening compounds in a reporter gene assay, inhibited the ESX–Sur2 interaction in a dose-dependent manner with potency similar to canertinib. The intervention of CHO10 during the E
Publikováno v:
BMC Cancer
Background A randomized clinical trial has found that the addition of erlotinib to gemcitabine (GEM-E) for pancreatic cancer led to a modest increase in survival. The aim of this national population-based retrospective study was to compare the effect
Hazard ration of survival. (DOCX 16 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca74fd9c21a0ec6520780e96f866c9f6
Autor:
Eung-Seok Lee, Jun Ho Lee, Eunyoung Lee, So Eun Park, Youngjoo Kwon, Kyu Yeon Jun, Pritam Thapa, Radha Karki, Hanbyeol Kwon
Publikováno v:
European journal of medicinal chemistry. 80
We describe our rationale for designing specific catalytic inhibitors of topoisomerase II (topo II) over topoisomerase I (topo I). Based on 3D-QSAR studies of previously published dihydroxylated 2,4-diphenyl-6-aryl pyridine derivatives, 9 novel dihyd
Autor:
Sangjin Shin, Chan Mi Park, Hanbyeol Kwon, Kyung-Hun Lee, Shin, Sangjin, Park, Chan Mi, Kwon, Hanbyeol, Lee, Kyung-Hun
Publikováno v:
BMC Cancer; 7/11/2016, Vol. 16, p1-7, 7p, 1 Diagram, 4 Charts, 1 Graph